Conclusion CCCC has a poor prognosis, stage for stage compared to other histologies. The FIGO stage, tumour size, lymphovascular space invasion and pelvic node status were factors that predicted the prognosis. Adjuvant radiotherapy or chemoradiotherapy have a limited role in the treatment of this rare cancer.

Disclosures The authors have no potential conflict of interest to disclose.

Introduction/Background HPV clearance and resolution of cervical HPV-dependent lesions become important in peri- and postmenopausal women. The objective of this sub-analysis was to evaluate the effect of the Papilocare®, a multi-ingredient Coriolus versicolor-based vaginal gel, on the normalization of cervical HPV-dependent atypia (ASCUS and LSIL) and associated colposcopic alterations in women older than 40 years.

Methodology Paloma clinical trial (ClinicalTrials.gov NCT04002154) was a multicenter, randomized, open-label, parallel-group, usual practice-controlled clinical trial. Unvaccinated HPV positive women aged between 30–65 with cytology of ASCUS or LSIL and concordant colposcopic image were randomized into 3 groups: A) Papilocare® 1 cannula/day for 1 month + 1 cannula/alternate days for 5 months; B) Papilocare® 1 cannula/day for 3 months + 1 cannula/alternate days for 3 months; C) Control group: no treatment.

Results A total of 41 out of 84 evaluated patients included in Paloma trial were older than 40y [mean (SD) age: 47.71 (5.56)], of which 30 and 13 were high-risk HPV and 16-18-31 HPV patients, respectively. Pap smear evaluations were blind and performed by brachytherapy. The median follow-up period was 47 months. The three-year DFS and OS were 13.3% and 13.3% respectively.

Conclusion Papilocare® showed a robust efficacy in normalizing cervical HPV lesions in women older than 40 years old, with a statistically significant difference vs control group in the total and high-risk populations.


All other authors have declared no conflicts of interest.

Introduction/Background Real-life studies inform on the effectiveness of a treatment what is intended to do in routine circumstances. The aim of this study is to evaluate the efficacy of Papilocare® - a multi-ingredient Coriolus versicolor-based vaginal gel- on repairing high-risk (HR) HPV-dependent low-degree cervical lesions and HR-HPV clearance in real-life practice.

Methodology Observational, multicenter, prospective, one-cohort study (PAPILOBS study ClinicalTrial.gov: NCT04199260). Currently recruiting 300 vaccinated or not HPV-positive women aged > 25y with Pap smear of ASCUS or LSIL and concordant colposcopy during routine clinical visits in Spain. Patients are treated with Papilocare® 1 cannula/day for 21 days the first month + 1 cannula/alternate days for 5 months. After this 6-month period, patients with altered cytology and/or HPV persistency are treated for a 6-month extension treatment period with the same dosage.

Interim analysis of HR-HPV patients with normal Pap smear and concordant colposcopy image (primary endpoint) and patient with HR-HPV cleared (patients with total clearance or partial clearance together with negative Pap smear and normal colposcopy) at 6/12 months is presented. The study was approved by the ethical committee of Public University Hospital of Puerta de Hierro (Madrid). Informed consent was signed by all patients.

Results At 6 months, data of 148 and 146 patients for Pap smear/colposcopy and HR-HPV presence, respectively, were available. 67.6% of patients (100/148) had negative Pap smear and concordant colposcopy. HR-HPV clearance was observed in 58.9% of patients (86/146). Data of 46 and 44 patients included in the 6-month extension treatment period for Pap smear/colposcopy and HR-HPV presence, respectively, were available. At 12 months, 78.3% (36/46) of patients had negative Pap smear and concordant colposcopy and HR-HPV clearance was observed in 70.5% (31/44). Considering all study period, 77% (114/148) and 72.6% (106/146) of patients repaired HR-HPV-dependent cervical lesions and cleared HR-HPV, respectively.

Conclusion In this interim analysis, repairing of HR-HPV-dependent low-degree cervical lesions and clearing HR-HPV, in real life conditions, was achieved after 6-month treatment

patients were treated with concurrent chemoradiation followed by brachytherapy. The median follow-up period was 47 months. The three-year DFS and OS were 13.3% and 13.3% respectively.